2023 News Archive
-
FDA Grants Priority Review for Avacincaptad Pegol
Friday February 17, 2023Iveric Bio announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The NDA has been granted priority review, meaning the FDA will act on the application within 6 months, rather than the 10 months typical under standard review.
-
New Retinal Physician news briefs
Friday February 3, 2023EyeArt AI System Receives EU Approval for AMD and Glaucoma Screening